

**Minutes of the June 8, 2013
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Debra Farver, PharmD; Timothy Soundy, MD; Bill Ladwig, RPh; Mikel Holland, MD; Kelly Oehlke, PharmD; Lenny Petrick, PharmD; Dana Darger, RPh; Michelle Baack, MD, Rick Holm, MD

Members absent

James Engelbrecht, MD

DSS staff present

Mike Jockheck, RPh; Ann Schwartz, Dep. Director of Medical Services

HID staff present

Candace Rieth, PharmD

Administrative Business

The P&T meeting was called to order by D. Darger at approximately 1:00pm. The minutes of the March 8, 2013 meeting were presented. D. Farver made a motion to approve. K. Oehlke seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for May 2013. There were a total of 2,513 PAs processed in the month of May, with 99.52% of those requests responded to in less than 8 hours. There were 1,882 (75%) requests received electronically and 631 (25%) requests received by fax.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 01/01/2013 – 03/31/2013. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, corticosteroids (respiratory tract) and central nervous system agents, misc. The top 15 therapeutic classes make up 39.05% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 11.08% of total claims. The committee requested that diabetic test strip utilization be presented at the September meeting.

Review of Drug Spend

C. Rieth reviewed SD Medicaid's drug spend for 2010-2012. M. Jockheck stated there were approximately 95,000-100,000 recipients pre-recession and now there are approximately 116,000.

Opiates Review

At the March 2013 meeting, the committee reviewed opiate utilization. The topic was brought back with additional utilization reports including de-identified recipient profiles. In March, the committee suggested that a top prescriber mailing be sent from the state. M. Jockheck stated that the draft is complete and the letter will go out soon. The committee requested that an update on the letter be presented at the September meeting along with information from other state Medicaid programs on how they are managing opiates. There was no public comment.

Proton Pump Inhibitor Review

C. Rieth presented utilization information for the proton pump inhibitors. This topic was tabled for the September meeting.

Sedative/Hypnotics Review

C. Rieth presented utilization and clinical information regarding the new FDA recommendations for zolpidem products. There was no public comment. R. Holm made a motion to require zolpidem IR 5mg for first time zolpidem prescriptions. B. Ladwig seconded the motion. The motion was approved unanimously. A trial of zolpidem IR 5mg will be required before zolpidem CR 6.25mg will be approved.

Onmel Review

C. Rieth presented clinical information for Onmel. There was no public comment. R. Holm made a motion to place Onmel on prior authorization. D. Farver seconded the motion. The motion was approved unanimously.

Giazo Review

C. Rieth presented clinical information for Giazo. This topic was tabled for the September meeting.

Delzicol Review

C. Rieth presented clinical information for Delzicol. This topic was tabled for the September meeting.

Diclegis Review

C. Rieth presented clinical information for Diclegis. There was no public comment. K. Oehlke made a motion to place Diclegis on prior authorization. D. Farver seconded the motion. The motion was approved unanimously.

The next meeting date is scheduled for September 20, 2013. A motion was made by D. Farver to adjourn the SD Medicaid P&T meeting. K. Oehlke seconded the motion. Motion passed unanimously and the meeting was adjourned.